It's happening. Again. String together a few biotech acquisitions or threats thereof, and suddenly every biotech is a takeout target.
Yesterday it was AstraZeneca taking out Ardea Biosciences, and last week it was Human Genome Sciences
But the names don't even matter. Put enough of them together, and investors will suddenly think they can buy any drugmaker and see an overnight double as the drugmaker gets taken out.
Sorry, Fools: It doesn't work that way. Good biotechs are in scarce supply, for sure, but pharma's cash isn't burning a hole it its pocket. Contrary to popular belief, they have more wherewithal than a 5-year- old in a candy store. In addition to just waiting for deals, share buybacks and dividends are viable options for using excess cash.
About the only place where the M&A-begets-M&A mantra made any sense is in the hepatitis C space. When a combination product is the only thing that's going to get you on the market, it's logical to snap up assets to round out the portfolio. Even so, there are still some hepatitis C biotechs that haven't been purchased -- Idenix Pharmaceuticals
But Ardea gets taken out, and suddenly you hear everyone talking about gout drugs. Sorry, but pharmas don't need a gout drug to fill their pipelines; they need any promising drug to fill the pipelines. And if Ardea is the best it gets, drugmakers playing second fiddle aren't going to have an advantage now that Ardea is out of the running.
The buy-your-partner rumors make even less sense. How does Glaxo's interest in its partner have any relevance over whether Bayer buys Onyx Pharmaceuticals
The reason pharma companies buy biotechs is the same reason you should buy biotechs. Either, like Human Genome Sciences and Amylin, they've been overly punished for their struggles, or, like Ardea, they have some upcoming catalyst that's worthy of holding over. Buying in the hopes that this string of M&A transaction will continue is a bad investment thesis.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
The Online Grocery Market Is Amazon's to Lose
Amazon's online grocery sales doubled its next closest competitor in 2017.
Social Security's 3 Purposes, and the 1 Thing It Was Never Intended For
America's most important social program is tasked with providing a financial backdrop for tens of millions of Americans.
3 Key Metrics for Duluth Holdings Investors to Watch
With most of the company’s growth tied to expanding retail sales, here are a few simple ways to measure its progress.